Imatinib Completed Phase 2 Trials for Recurrent Neuroendocrine Carcinoma of the Skin / Stage II Neuroendocrine Carcinoma of the Skin / Stage III Neuroendocrine Carcinoma of the Skin Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00068783S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer